Evaluation of 68Ga-FAPI radiotracer in lung cancer
- Conditions
- ung cancer.Malignant neoplasm of bronchus and lung
- Registration Number
- IRCT20220817055732N1
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
A patient with lung cancer proven in pathology
A patient with lung cancer in the staging phase
Patients do not accept the offer of PET-CT with 68Ga-FAPI radiopharmaceutical after providing the necessary explanations and answering their questions.
Patients withdraw from the study before the scan.
Uncontrolled diseases (such as fatal arrhythmias) that require hospitalization.
Suffering from mental illnesses that take away the ability to make decisions and cooperate.
Pregnant or lactating women.
Suffering from physical diseases that disrupt the imaging process.
The death of the patient in the interval between the two studied scans.
History of cancer other than lung cancer
History of active inflammatory/infectious disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The number of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Localization of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Size of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.;Shape of malignant lesions in selected patients. Timepoint: After PET-CT imaging of the patients with 18FDG and 68Ga-FAPI radiotracers. Method of measurement: Investigation of PET-CT scans.
- Secondary Outcome Measures
Name Time Method